albuterol
Pre-clinical- Indications
- Asthma, COPD
Company intelligence / Profile preview
DevPro Biopharma has completed early feasibility studies on a next-generation low-emission albuterol inhaler with comparable efficacy to Ventolin HFA but with near-zero global warming potential. The company is also advancing an anti–TSLP monoclonal antibody into Phase 2 trials for asthma and COPD through partnership with Uniquity Bio. The team has contributed to over fifty approved products or label expansions globally across multiple therapeutic areas over the past thirty years.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on DevPro Biopharma.